Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab.

ABSTRACT:

Background

Although PD-1 antibodies (PD1 Ab) are the standard of care for advanced non-small-cell lung cancer (ansclc), most patients will progress. We compared survival outcomes for patients with ansclc who received systemic therapy (st) after progression and for those who did not. Additionally, clinical characteristics that predicted receipt of st after PD1 Ab failure were evaluated.

Methods

All patients with ansclc in British Columbia initiated on nivolumab or pembrolizumab between June 2015 and November 2017, with subsequent progression, were identified. Eligibility criteria for additional st included an Eastern Cooperative Oncology Group (ecog) performance status (ps) of 3 or less and survival for more than 30 days from the last PD1 Ab treatment. Post-progression surviv

SUBMITTER: Freeman AT 

PROVIDER: S-EPMC7253749 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature